Neurophth Therapeutics
↗Wuhan, China
Neurophth Therapeutics is a China-based, fully integrated genomic medicines company dedicated to developing gene therapies for ophthalmic diseases. Founded in 2016, the company utilizes a proprietary AAV (adeno-associated virus) gene therapy platform to address genetic eye disorders, including Leber's hereditary optic neuropathy (LHON), autosomal dominant optic atrophy, and vascular retinopathy.
Headquartered in Wuhan, China, with additional facilities in Shanghai, Suzhou, and San Diego, USA, Neurophth is a pioneer in the Chinese ophthalmology gene therapy space. The company has established state-of-the-art cGMP manufacturing capabilities to support its global clinical development and future commercialization efforts.
CLASSIFICATION
SIZE & FINANCIALS
Employees:201-500
Founded:2016
Ownership:private
Status:operating
FUNDING
Stage:Series C+
Total Raised:$125M+
Investors:CMG-SDIC Capital, Sequoia Capital China, Yangtze River Industry Fund, Wuhan Optical Valley Financial Holding Group, Wuhan Hi-Tech Holding Group, Sunshine Insurance
PIPELINE
Stage:Phase 3
Lead Drug Stage:Phase 3
Modalities:Gene therapy, AAV vector
Active Trials:3
Trial Phases:Phase 1: 2 | Phase 2: 2 | Phase 3: 1
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Subsidiaries:Neurophth Therapeutics (USA) Inc.
Key Partnerships:Cyagen (AI platform for AAV vector discovery), Hopstem (stem cells), AAVnerGene (capsids)
COMPETITION
Position:Emerging
Competitors:Molecular Partners, CureVac, Rezolute
LEADERSHIP
Key Executives:
Bin Li - Founder, Chairman and CEO
Xiaoning Guo - Chief Medical Officer
Qiutang Li - Chief Scientific Officer
Scientific Founders:Bin Li
LINKS
Website:neurophth.com
⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Neurophth Therapeutics and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Neurophth Therapeutics. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.